GSK and Theravance announce FDA acceptance of FF/VI NDA submission in the US for COPD
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
List view / Grid view
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
13 July 2012 | By GlaxoSmithKline
Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US...
2 July 2012 | By GlaxoSmithKline
Results from the pivotal efficacy studies...
16 May 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced that following approval by Theravance...
23 March 2012 | By GlaxoSmithKline
COPD and asthma regulatory plans remain on track for submission from mid-2012...
9 January 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced the completion of the phase III registration programme...
29 November 2010 | By GlaxoSmithKline
GlaxoSmithKline and Theravance, Inc. announced today that GSK will increase its shareholding in Theravance through the purchase of Theravance common stock in a private placement...